{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:19:13Z","timestamp":1786119553069,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1097\/ftd.0b013e3181f2f24f","type":"journal-article","created":{"date-parts":[[2010,9,15]],"date-time":"2010-09-15T06:50:04Z","timestamp":1284533404000},"page":"669-672","source":"Crossref","is-referenced-by-count":13,"title":["Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: What Do We Know?"],"prefix":"10.1097","volume":"32","author":[{"given":"Alfredo","family":"Tartarone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Lerose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210129","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs.","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"R2-1-20210129","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"R3-1-20210129","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1081-1206(10)61112-X","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature.","volume":"94","author":"Letko","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R4-1-20210129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Jones syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-Study.","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"R5-1-20210129","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4103\/0378-6323.16782","article-title":"Carbamazepine, the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7 years.","volume":"71","author":"Devi","year":"2005","journal-title":"Indian Dermatol Venereol Leprol"},{"key":"R6-1-20210129","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0140-6736(98)05418-X","article-title":"Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on severe cutaneous adverse reactions.","volume":"353","author":"Rzany","year":"1999","journal-title":"Lancet"},{"key":"R7-1-20210129","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.","volume":"58","author":"Halevy","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R8-1-20210129","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1529-8019.2009.01260.x","article-title":"Clinical risk management of Stevens-Johnson syndrome\/toxic epidermal necrolysis spectrum.","volume":"22","author":"Knowles","year":"2009","journal-title":"Dermatology Therapy"},{"key":"R9-1-20210129","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis.","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R10-1-20210129","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.autrev.2005.10.003","article-title":"Toxic epidermal necrolysis in systemic lupus erythematosus.","volume":"5","author":"Horne","year":"2006","journal-title":"Autoimmun Rev"},{"key":"R11-1-20210129","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0190-9622(92)70082-Q","article-title":"Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus.","volume":"26","author":"Saiag","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"R12-1-20210129","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.autrev.2008.06.004","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"7","author":"Borchers","year":"2008","journal-title":"Autoimmunity Reviews"},{"key":"R13-1-20210129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2559.2009.03442.x","article-title":"Blistering skin disease: a bridge between dermatopathology and molecular biology.","volume":"56","author":"Nagy","year":"2010","journal-title":"Histopathology"},{"key":"R14-1-20210129","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0300-483X(95)03253-C","article-title":"T cell immune response to haptens: structural models for allergic and autoimmune reactions.","volume":"107","author":"Weltzien","year":"1996","journal-title":"Toxicology"},{"key":"R15-1-20210129","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11532540-000000000-00000","article-title":"New insights in toxic epidermal necrolysis (Lyells syndrome). Clinical considerations, pathobiology and targeted treatments revisited.","volume":"33","author":"Paquet","year":"2010","journal-title":"Drug Saf"},{"key":"R16-1-20210129","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00130832-200208000-00003","article-title":"Pharmacological interaction of drugs with antigen-specific immune receptor: the p-i concept.","volume":"2","author":"Pichler","year":"2002","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R17-1-20210129","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000097652","article-title":"Glutathione-S-transferase expression in toxic epidermal necrolysis: a marker of putative oxidative stress in keratinocytes.","volume":"20","author":"Paquet","year":"2007","journal-title":"Skin Pharmacol Physiol"},{"key":"R18-1-20210129","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3109\/10409239509083491","article-title":"The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance.","volume":"30","author":"Hayes","year":"1995","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"R19-1-20210129","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.burns.2009.06.213","article-title":"Toxic epidermial necrolysis (Lyells disease).","volume":"36","author":"Lissia","year":"2010","journal-title":"Burns"},{"key":"R20-1-20210129","first-page":"348","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme.","volume":"25","author":"Roujeau","year":"2007","journal-title":"J Dermatol"},{"key":"R21-1-20210129","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.clindermatol.2007.01.001","article-title":"In the pursuit of classifying severe cutaneous adverse reactions.","volume":"25","author":"Wolf","year":"2007","journal-title":"Clin Dermatol"},{"key":"R22-1-20210129","first-page":"1883","article-title":"Erythema multiforme.","volume":"74","author":"Lamoreux","year":"2006","journal-title":"Am Fam Physician"},{"key":"R23-1-20210129","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study in patients included in the prospective EuroSCAR Study.","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R24-1-20210129","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/pgmj.2007.061465","article-title":"Management of toxic epidermal necrolysis and related syndromes.","volume":"84","author":"Mukasa","year":"2008","journal-title":"Postgrad Med J"},{"key":"R25-1-20210129","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"R26-1-20210129","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0305-4179(01)00005-5","article-title":"Treatment of drug-induced toxic epidermal necrolysis (Lyell syndrome) with intravenous human immunoglobulins.","volume":"27","author":"Paquet","year":"2001","journal-title":"Burns"},{"key":"R27-1-20210129","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1365-4632.2007.03277.x","article-title":"Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome.","volume":"46","author":"Fromowitz","year":"2007","journal-title":"Int J Dermatol"},{"key":"R28-1-20210129","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2133.2005.06721.x","article-title":"Toxic epidermal necrolysis: current evidence, practical management and future directions.","volume":"153","author":"Chave","year":"2005","journal-title":"Br J Dermatol"},{"key":"R29-1-20210129","first-page":"340","article-title":"Toxic epidermal necrolysis: a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids.","volume":"180","author":"Herndon","year":"1995","journal-title":"J Am Coll Surg"},{"key":"R30-1-20210129","first-page":"283","article-title":"Burn center care for patients with toxic epidermal necrolysis.","volume":"180","author":"Kelemen","year":"1995","journal-title":"J Am Coll Surg"},{"key":"R31-1-20210129","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1365-4632.2009.04166.x","article-title":"Combination therapy of intravenous immunoglobulin and corticosteroids in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.","volume":"48","author":"Yang","year":"2009","journal-title":"Int J Dermatol"},{"key":"R32-1-20210129","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis.","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"R33-1-20210129","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMct0806956","article-title":"Parenteral nutrition in the critically ill patient.","volume":"361","author":"Ziegler","year":"2009","journal-title":"N Engl J Med"},{"key":"R34-1-20210129","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity of illness score for toxic epidermal necrolysis.","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e3181f2f24f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:34:31Z","timestamp":1786041271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-201012000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181f2f24f","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}